Paradigm Capital Management Inc. NY Invests $3.44 Million in AtriCure, Inc. $ATRC

Paradigm Capital Management Inc. NY bought a new position in shares of AtriCure, Inc. (NASDAQ:ATRC) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 123,100 shares of the medical device company’s stock, valued at approximately $3,444,000.

A number of other large investors have also made changes to their positions in the stock. Bank of America Corp DE grew its holdings in AtriCure by 13.7% in the 1st quarter. Bank of America Corp DE now owns 768,561 shares of the medical device company’s stock valued at $21,927,000 after buying an additional 92,830 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of AtriCure in the second quarter valued at about $1,744,000. Rice Hall James & Associates LLC acquired a new stake in AtriCure during the second quarter worth about $3,755,000. F m Investments LLC acquired a new stake in AtriCure during the fourth quarter worth about $2,872,000. Finally, Vanguard Group Inc. raised its stake in AtriCure by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock worth $193,993,000 after purchasing an additional 62,861 shares during the period. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at AtriCure

In other AtriCure news, Director Maggie Yuen sold 3,500 shares of the business’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $38.42, for a total value of $134,470.00. Following the completion of the transaction, the director owned 14,015 shares in the company, valued at $538,456.30. The trade was a 19.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Sven Wehrwein sold 25,000 shares of the company’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $37.84, for a total value of $946,000.00. Following the sale, the director directly owned 40,518 shares in the company, valued at $1,533,201.12. This represents a 38.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 44,246 shares of company stock worth $1,691,895 over the last 90 days. 4.00% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Weiss Ratings upgraded shares of AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 19th. Citigroup restated a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Canaccord Genuity Group lifted their price target on shares of AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. BTIG Research upped their price objective on AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a report on Monday. Finally, Zacks Research upgraded AtriCure from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 24th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $48.62.

AtriCure Stock Up 0.6%

Shares of NASDAQ:ATRC opened at $49.28 on Tuesday. The firm has a market capitalization of $2.51 billion, a PE ratio of 234.68 and a beta of 1.20. AtriCure, Inc. has a 1 year low of $25.36 and a 1 year high of $49.88. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. The firm’s 50-day moving average is $36.25 and its two-hundred day moving average is $31.89.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The business had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same quarter last year, the firm posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Analysts predict that AtriCure, Inc. will post 0.2 EPS for the current year.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.